Multivariable Logistic Regression Results of Patient and Treatment Factors Associated With Odds of Longer-Term Survival (>3 years) After Diagnosis With Glioblastoma, NCDB 2005–2015
| . | Univariable OR (95% CI) . | P . | Multivariable OR (95% CI) . | P . |
|---|---|---|---|---|
| Age (years) | ||||
| 70 | Reference | Reference | ||
| <60 | 5.58 (5.17–6.02) | <.0001 | 4.46 (4.11–4.84) | <.0001 |
| 60–70 | 2.60 (2.39–2.82) | <.0001 | 2.22 (2.04–2.43) | <.0001 |
| Sex | ||||
| Male | Reference | Reference | ||
| Female | 1.15 (1.10–1.2) | <.0001 | 1.19 (1.19–1.31) | <.0001 |
| Race | ||||
| White | Reference | Reference | ||
| Black | 1.26 (1.15–1.38) | <.0001 | 1.19 (1.08–1.32) | .0008 |
| Others | 1.69 (1.53–1.87) | <.0001 | 1.58 (1.40–1.79) | <.0001 |
| Ethnicity | ||||
| Non-Hispanic | Reference | Reference | ||
| Hispanic | 1.56 (1.43–1.72) | <.0001 | 1.45 (1.31–1.60) | <.0001 |
| Charlson/Deyo score | ||||
| ≥3 | Reference | Reference | ||
| 0 | 2.49 (2.11–2.93) | <.0001 | 1.92 (1.61–2.28) | <.0001 |
| 1 | 1.53 (1.29–1.82) | <.0001 | 1.42 (1.18–1.71) | .0001 |
| 2 | 1.28 (1.06–1.55) | .009 | 1.17 (0.96–1.44) | .1162 |
| Tumor location | ||||
| Infratentorial | Reference | Reference | ||
| Supratentorial | 1.28 (1.01–1.62) | .0438 | 1.58 (1.21–2.06) | .0007 |
| Others | 0.92 (0.72–1.17) | .5142 | 1.22 (0.93–1.59) | .1513 |
| Treatment type | ||||
| Radiation only | Reference | Reference | ||
| Chemotherapy only | 1.89 (1.09–3.29) | .024 | 1.40 (0.79–2.47) | .2506 |
| Radiation + chemotherapy | 2.59 (1.88–3.58) | <.0001 | 1.88 (1.36–2.61) | .0001 |
| Surgery only | 2.75 (2.00–3.78) | <.0001 | 2.30 (1.66–3.17) | <.0001 |
| Surgery + radiation | 3.27 (2.35–4.54) | <.0001 | 2.57 (1.84–3.58) | <.0001 |
| Surgery + chemotherapy | 5.00 (3.56–7.01) | <.0001 | 3.73 (2.65–5.25) | <.0001 |
| All modalities | 7.65 (5.61–10.43) | <.0001 | 4.89 (3.58 - 6.68) | <.0001 |
| . | Univariable OR (95% CI) . | P . | Multivariable OR (95% CI) . | P . |
|---|---|---|---|---|
| Age (years) | ||||
| 70 | Reference | Reference | ||
| <60 | 5.58 (5.17–6.02) | <.0001 | 4.46 (4.11–4.84) | <.0001 |
| 60–70 | 2.60 (2.39–2.82) | <.0001 | 2.22 (2.04–2.43) | <.0001 |
| Sex | ||||
| Male | Reference | Reference | ||
| Female | 1.15 (1.10–1.2) | <.0001 | 1.19 (1.19–1.31) | <.0001 |
| Race | ||||
| White | Reference | Reference | ||
| Black | 1.26 (1.15–1.38) | <.0001 | 1.19 (1.08–1.32) | .0008 |
| Others | 1.69 (1.53–1.87) | <.0001 | 1.58 (1.40–1.79) | <.0001 |
| Ethnicity | ||||
| Non-Hispanic | Reference | Reference | ||
| Hispanic | 1.56 (1.43–1.72) | <.0001 | 1.45 (1.31–1.60) | <.0001 |
| Charlson/Deyo score | ||||
| ≥3 | Reference | Reference | ||
| 0 | 2.49 (2.11–2.93) | <.0001 | 1.92 (1.61–2.28) | <.0001 |
| 1 | 1.53 (1.29–1.82) | <.0001 | 1.42 (1.18–1.71) | .0001 |
| 2 | 1.28 (1.06–1.55) | .009 | 1.17 (0.96–1.44) | .1162 |
| Tumor location | ||||
| Infratentorial | Reference | Reference | ||
| Supratentorial | 1.28 (1.01–1.62) | .0438 | 1.58 (1.21–2.06) | .0007 |
| Others | 0.92 (0.72–1.17) | .5142 | 1.22 (0.93–1.59) | .1513 |
| Treatment type | ||||
| Radiation only | Reference | Reference | ||
| Chemotherapy only | 1.89 (1.09–3.29) | .024 | 1.40 (0.79–2.47) | .2506 |
| Radiation + chemotherapy | 2.59 (1.88–3.58) | <.0001 | 1.88 (1.36–2.61) | .0001 |
| Surgery only | 2.75 (2.00–3.78) | <.0001 | 2.30 (1.66–3.17) | <.0001 |
| Surgery + radiation | 3.27 (2.35–4.54) | <.0001 | 2.57 (1.84–3.58) | <.0001 |
| Surgery + chemotherapy | 5.00 (3.56–7.01) | <.0001 | 3.73 (2.65–5.25) | <.0001 |
| All modalities | 7.65 (5.61–10.43) | <.0001 | 4.89 (3.58 - 6.68) | <.0001 |
OR, odds ratio; 95% CI, 95% confidence interval.
All modalities: surgery + radiotherapy + chemotherapy.
Multivariable Logistic Regression Results of Patient and Treatment Factors Associated With Odds of Longer-Term Survival (>3 years) After Diagnosis With Glioblastoma, NCDB 2005–2015
| . | Univariable OR (95% CI) . | P . | Multivariable OR (95% CI) . | P . |
|---|---|---|---|---|
| Age (years) | ||||
| 70 | Reference | Reference | ||
| <60 | 5.58 (5.17–6.02) | <.0001 | 4.46 (4.11–4.84) | <.0001 |
| 60–70 | 2.60 (2.39–2.82) | <.0001 | 2.22 (2.04–2.43) | <.0001 |
| Sex | ||||
| Male | Reference | Reference | ||
| Female | 1.15 (1.10–1.2) | <.0001 | 1.19 (1.19–1.31) | <.0001 |
| Race | ||||
| White | Reference | Reference | ||
| Black | 1.26 (1.15–1.38) | <.0001 | 1.19 (1.08–1.32) | .0008 |
| Others | 1.69 (1.53–1.87) | <.0001 | 1.58 (1.40–1.79) | <.0001 |
| Ethnicity | ||||
| Non-Hispanic | Reference | Reference | ||
| Hispanic | 1.56 (1.43–1.72) | <.0001 | 1.45 (1.31–1.60) | <.0001 |
| Charlson/Deyo score | ||||
| ≥3 | Reference | Reference | ||
| 0 | 2.49 (2.11–2.93) | <.0001 | 1.92 (1.61–2.28) | <.0001 |
| 1 | 1.53 (1.29–1.82) | <.0001 | 1.42 (1.18–1.71) | .0001 |
| 2 | 1.28 (1.06–1.55) | .009 | 1.17 (0.96–1.44) | .1162 |
| Tumor location | ||||
| Infratentorial | Reference | Reference | ||
| Supratentorial | 1.28 (1.01–1.62) | .0438 | 1.58 (1.21–2.06) | .0007 |
| Others | 0.92 (0.72–1.17) | .5142 | 1.22 (0.93–1.59) | .1513 |
| Treatment type | ||||
| Radiation only | Reference | Reference | ||
| Chemotherapy only | 1.89 (1.09–3.29) | .024 | 1.40 (0.79–2.47) | .2506 |
| Radiation + chemotherapy | 2.59 (1.88–3.58) | <.0001 | 1.88 (1.36–2.61) | .0001 |
| Surgery only | 2.75 (2.00–3.78) | <.0001 | 2.30 (1.66–3.17) | <.0001 |
| Surgery + radiation | 3.27 (2.35–4.54) | <.0001 | 2.57 (1.84–3.58) | <.0001 |
| Surgery + chemotherapy | 5.00 (3.56–7.01) | <.0001 | 3.73 (2.65–5.25) | <.0001 |
| All modalities | 7.65 (5.61–10.43) | <.0001 | 4.89 (3.58 - 6.68) | <.0001 |
| . | Univariable OR (95% CI) . | P . | Multivariable OR (95% CI) . | P . |
|---|---|---|---|---|
| Age (years) | ||||
| 70 | Reference | Reference | ||
| <60 | 5.58 (5.17–6.02) | <.0001 | 4.46 (4.11–4.84) | <.0001 |
| 60–70 | 2.60 (2.39–2.82) | <.0001 | 2.22 (2.04–2.43) | <.0001 |
| Sex | ||||
| Male | Reference | Reference | ||
| Female | 1.15 (1.10–1.2) | <.0001 | 1.19 (1.19–1.31) | <.0001 |
| Race | ||||
| White | Reference | Reference | ||
| Black | 1.26 (1.15–1.38) | <.0001 | 1.19 (1.08–1.32) | .0008 |
| Others | 1.69 (1.53–1.87) | <.0001 | 1.58 (1.40–1.79) | <.0001 |
| Ethnicity | ||||
| Non-Hispanic | Reference | Reference | ||
| Hispanic | 1.56 (1.43–1.72) | <.0001 | 1.45 (1.31–1.60) | <.0001 |
| Charlson/Deyo score | ||||
| ≥3 | Reference | Reference | ||
| 0 | 2.49 (2.11–2.93) | <.0001 | 1.92 (1.61–2.28) | <.0001 |
| 1 | 1.53 (1.29–1.82) | <.0001 | 1.42 (1.18–1.71) | .0001 |
| 2 | 1.28 (1.06–1.55) | .009 | 1.17 (0.96–1.44) | .1162 |
| Tumor location | ||||
| Infratentorial | Reference | Reference | ||
| Supratentorial | 1.28 (1.01–1.62) | .0438 | 1.58 (1.21–2.06) | .0007 |
| Others | 0.92 (0.72–1.17) | .5142 | 1.22 (0.93–1.59) | .1513 |
| Treatment type | ||||
| Radiation only | Reference | Reference | ||
| Chemotherapy only | 1.89 (1.09–3.29) | .024 | 1.40 (0.79–2.47) | .2506 |
| Radiation + chemotherapy | 2.59 (1.88–3.58) | <.0001 | 1.88 (1.36–2.61) | .0001 |
| Surgery only | 2.75 (2.00–3.78) | <.0001 | 2.30 (1.66–3.17) | <.0001 |
| Surgery + radiation | 3.27 (2.35–4.54) | <.0001 | 2.57 (1.84–3.58) | <.0001 |
| Surgery + chemotherapy | 5.00 (3.56–7.01) | <.0001 | 3.73 (2.65–5.25) | <.0001 |
| All modalities | 7.65 (5.61–10.43) | <.0001 | 4.89 (3.58 - 6.68) | <.0001 |
OR, odds ratio; 95% CI, 95% confidence interval.
All modalities: surgery + radiotherapy + chemotherapy.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
